Expert Interview
A Second Look: Discussing FcRn and CD19 as a target in primary immune thrombocytopenia (ITP)
Ticker(s): ARGX, AMGN, ELYMInstitution: Keck Medicine at USC
- Professor of Medicine and Pathology at Keck Medicine
- Lab is currently studying the genetic risk factors responsible for thrombotic diseases including venous thrombosis, pulmonary embolism, and arterial thrombosis.
- Internationally known for his work in the relationships between venous thrombotic disease and underlying malignancy. He has been and is the principal investigator on several clinical trials in the management of immune thrombocytopenia (ITP)
Roughly how many patients with ITP do you currently manage?
Added By: wilson_adminWhat are your views on Rituximab's efficacy in treating ITP, particularly regarding its effectiveness in younger women and the challenges of long-term remission?
How do you evaluate the mixed data on FcRn-targeting drugs, specifically the IV and Sub-Q formulations, in managing ITP, and what are the potential implications of these results?
What insights can you provide on the early data for CD38 and CD19 as targets in ITP, particularly regarding their mechanisms of action and the potential for durable responses in different patient populations?
How significant is the role of CD19, especially in the context of CAR T-cell therapy for refractory ITP, and what are the prospects and challenges of using monoclonal or bispecific antibodies targeting CD19?
What are your thoughts on alternative targets like BAFF, APRIL, and other emerging therapies in ITP, and how do they compare with existing treatments like Tpo agonists and anti-CD20 therapies?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
